{
  "docId": "019de075-da5f-7126-b0c8-5ad6b3fad507",
  "docSlug": "2367b4018d9bb2d1e01ea441f685753d",
  "documentTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides",
  "authorId": "neumora-therapeutics",
  "authorName": "Neumora Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 18,
  "pageCount": 32,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/18",
  "deckHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507",
  "deckJsonHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json",
  "deckAnchorHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.55,
        "x": 0.42,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Interim assessment using effect size in adaptive signal-seeking study provides opportunity to make an informed decision on advancing NMRA-511 program most efficiently",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25ebe95f-6c04-4bc1-b77d-2f079d3f793c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.36,
        "x": 0.03,
        "y": 0.52
      },
      "kind": "chart",
      "text": "Marmoset and Human EEG data showing change from baseline for theta and alpha waves.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e688e188-defa-4352-af2e-00fcc817227f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.55,
        "x": 0.42,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Stage 1: Signal Seeking adaptive study design flow.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd4bf560-f7de-402c-9c52-78a9fd1cec74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.36,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "In a human threat test study completed in marmosets, NMRA-511 demonstrated activity in brain circuits that regulate mood and anxiety. An additional EEG study demonstrated that the pharmacodynamic effects of NMRA-511 translated to humans.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1c6ce48-9c37-4288-a0fa-8d11f3dbbb3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1) Wallace TL. et al, NMRA-511, a novel vasopressin 1a (V1a) receptor antagonist reduces threat behaviors in marmosets and alters EEG power spectra similarly in marmosets and humans. Presented at the American College of Neuropsychopharmacology 2022 Annual Congress.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "addf0ce9-7bc5-48c8-b6ab-6fbda6e0e0db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "NMRA-511 Demonstrates Relevant Pharmacodynamics with the Potential to Address Anxiety Disorders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6267022-f395-4302-a270-0b5a4e524110",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "adaptive-clinical-trial-design",
      "slug": null,
      "matchId": "cc8a6ce4-e3c4-4157-8ca3-154d1c5a593d",
      "evidence": "The diagram illustrates a signal-seeking stage with decision gates based on effect size.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}